Psychotropic Drugs in Dementia

Why Are Psychotropic Drugs Prescribed to Dementia Patients?

Behavioral and psychological symptoms of dementia (BPSD)—including agitation, aggression, hallucinations, and disrupted sleep—affect the majority of patients at some point during their illness. When these symptoms escalate, particularly in acute care environments, clinicians often turn to psychotropic medications such as antipsychotics, benzodiazepines, antidepressants, and mood stabilizers to manage immediate distress and ensure safety.

However, major guidelines from the American Geriatrics Society, the Alzheimer's Association, and similar bodies emphasize that non-pharmacological interventions—environmental modifications, structured activities, caregiver training, and addressing unmet needs such as pain or hunger—should be tried before drug therapy. The FDA has issued black box warnings on antipsychotics for elderly patients with dementia due to increased risk of stroke and death, yet prescriptions in this population remain common, particularly when symptoms emerge during hospitalization or rehabilitation stays.

What Did the New Study Find About Long-Term Use?

Researchers analyzed prescribing patterns among older adults with dementia who were newly started on psychotropic medications. The findings show that emergency rooms, inpatient hospital units, and skilled nursing facilities account for a disproportionate share of these new prescriptions—settings where patients are often acutely ill, delirious, or recovering from procedures, and where behavioral symptoms can be especially challenging to manage.

Most concerning, approximately half of patients who start a psychotropic in these settings remain on it 12 months later. This pattern suggests that medications intended for short-term crisis management frequently become permanent fixtures of a patient's drug regimen, often without formal reassessment. Once a patient is discharged, communication gaps between hospital teams and primary care providers can leave nobody clearly responsible for tapering or stopping the drug, even when the original indication has resolved.

How Can Deprescribing Reduce Harm in Older Adults?

Deprescribing—the planned reduction or discontinuation of medications that may be causing more harm than benefit—has emerged as a priority in geriatric medicine. For psychotropics in dementia, evidence suggests gradual tapering is generally safe and often improves function, alertness, and fall risk without worsening behavioral symptoms in most patients.

Effective strategies include mandatory medication reviews at every care transition, clear documentation of the indication and intended duration when a psychotropic is started, and shared decision-making with families about goals of care. Health systems are increasingly adopting electronic prompts and pharmacist-led review programs to flag long-term psychotropic use in dementia patients, supporting clinicians in reassessing whether these drugs are still needed.